Annovis Bio (ANVS) AI Stock Analysis

• Market Cap: $84.01M
• Dividend Yield: N/A
• Average Volume (3M): 599.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.19
• Revenue Growth: N/A
• EPS Growth: 62.84%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.37
• Shares Outstanding: 26,502,890
• 10 Day Avg. Volume: 514,664
• 30 Day Avg. Volume: 599,593
• PEG Ratio: >-0.01
• Price to Book (P/B): 6.58
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 0.30
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.96
• 1Y Price Target: $12.50
• Price Target Upside: 290.63% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -1.37
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $3.50 ▲(9.37% Upside)

The score is primarily held down by weak financial performance (pre-revenue, ongoing losses and cash burn) and a valuation profile dominated by negative earnings. Technicals are mixed (better longer-term trend but weaker near-term), and the recent $6M equity raise modestly helps funding runway while adding dilution risk.

Positive Factors

Debt-Free Balance Sheet

A debt-free balance sheet provides financial flexibility, allowing the company to allocate resources towards R&D and strategic initiatives without the burden of interest payments.

Phase 3 Alzheimer's Study

The launch of a Phase 3 study represents a critical step towards potential drug approval, which could lead to future revenue streams and strengthen the company's market position in neurodegenerative therapies.

Innovative Drug Development

Focusing on innovative therapies for neurodegenerative diseases positions Annovis Bio in a growing market with significant unmet medical needs, potentially leading to breakthrough treatments and competitive advantages.

Negative Factors

Zero Revenue

Consistent zero revenue highlights the company's reliance on external funding and underscores the risk associated with its current stage of development, impacting financial sustainability.

NYSE Non-Compliance Notice

The NYSE non-compliance notice reflects financial pressures and could lead to delisting, affecting investor confidence and access to capital markets if not addressed.

Negative Cash Flow

Negative cash flow indicates a dependency on external funding, which can strain resources and limit the company's ability to sustain operations without successful fundraising or revenue generation.

Annovis Bio Business Overview & Revenue Model

Company Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

How the Company Makes Money

Annovis Bio generates revenue primarily through the development and potential commercialization of its therapeutic candidates. The company's revenue model is centered around advancing its drug candidates through clinical trials and eventually receiving regulatory approval for commercialization. Once a drug is approved, Annovis Bio may earn money through direct sales, licensing agreements, or partnerships with larger pharmaceutical companies for distribution and marketing. Additionally, the company may also receive funding from grants or collaborative research agreements with other institutions. However, as a clinical-stage company, Annovis Bio may not currently have significant revenue streams from commercialized products.

Annovis Bio Financial Statement Overview

Summary

Annovis Bio's financial performance is weak due to zero revenue and increasing net losses, which is common for early-stage biotech firms. The balance sheet is hampered by negative equity at times, despite having no debt. Cash flows are negative, indicating reliance on external funding.

Income Statement

Annovis Bio has reported zero revenue consistently since 2019, which is a significant concern for sustainability. The company has faced increasing net losses, with the latest annual report showing a net loss of approximately $24.59 billion. The lack of revenue and growing losses reflect poor financial health from an income perspective, typical for early-stage biotechnology firms focusing on R&D without a commercialized product.

Balance Sheet

The balance sheet shows that Annovis Bio has no debt, which is a positive sign. However, the company has a negative equity at times and fluctuating stockholders' equity, indicating financial instability. The equity ratio has been erratic, and the lack of tangible revenue-generating assets further complicates its financial stability.

Cash Flow

Operating cash flows have been consistently negative, reflecting the company's ongoing investments in operations without incoming cash flow from sales. While financing activities have provided some relief, the overall cash flow situation highlights a dependency on external funding to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-26.55M	-26.69M	-45.03M	-25.51M	-14.50M	0.00
Net Income	-24.88M	-24.59M	-56.20M	-25.33M	-14.49M	-5.46M
Balance Sheet
Total Assets	17.19M	13.93M	10.21M	36.02M	46.00M	8.12M
Cash, Cash Equivalents and Short-Term Investments	15.29M	10.55M	5.75M	28.38M	45.69M	8.07M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	4.03M	4.62M	17.96M	7.70M	1.51M	578.38K
Stockholders Equity	13.16M	9.31M	-7.75M	28.32M	44.49M	7.54M
Cash Flow
Free Cash Flow	-24.98M	-21.89B	-39.97M	-17.31M	-9.13M	-3.97M
Operating Cash Flow	-24.98M	-21.89B	-39.97M	-17.31M	-9.13M	-3.97M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	27.63M	26.69B	17.34M	4.61K	46.74M	12.04M

Annovis Bio Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.20
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANVS, the sentiment is Neutral. The current price of 3.2 is below the 20-day moving average (MA) of 3.60, below the 50-day MA of 3.58, and above the 200-day MA of 2.55, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 40.63 is Neutral, neither overbought nor oversold. The STOCH value of 15.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ANVS.

Annovis Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WHWK	56 Neutral	$136.67M	20.54	-13.82%	―	-42.62%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ABOS	48 Neutral	$108.43M	-0.84	-85.93%	―	―	-60.99%
COYA	48 Neutral	$97.09M	-3.66	-62.18%	―	-58.26%	-53.20%
ANVS	46 Neutral	$84.01M	-2.16	-246.14%	―	―	62.84%
DTIL	46 Neutral	$99.42M	-0.46	-205.16%	―	-99.07%	-10347.56%

Annovis Bio Corporate Events

Annovis Bio Announces Securities Purchase Agreement

On October 26, 2025, Annovis Bio, Inc. entered into a Securities Purchase Agreement to issue and sell 597,561 shares of common stock in a registered direct offering, along with Stock Subscription Agreements for an additional 1,073,171 shares. The offering is expected to raise approximately $3.425 million, which will be used for the clinical development of Buntanetap and general corporate purposes. The offering is set to close on October 28, 2025, and includes restrictions on the issuance of additional securities until November 28, 2025, and October 14, 2026, respectively. The company engaged a Placement Agent, agreeing to a 7% cash fee and issuing warrants for 83,537 shares.

The most recent analyst rating on (ANVS) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Annovis Bio stock, see the ANVS Stock Forecast page.